Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over β-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.
本文披露了用于β-连环蛋白/BCL9相互作用的
抑制剂。这些
抑制剂在β-连环蛋白/BCL9与β-连环蛋白/cadherin相互作用中具有选择性。还披露了使用这些披露的化合物来治疗癌症的方法。